Engineering a Human Physiomimetic Islet Microsystem
Engineering a Human Physiomimetic Islet Microsystem
批准号:
8813808
负责人:
Ashutosh Agarwal
金额:
$487.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-20 至 2019-06-30
关键词:
3-DimensionalAddressAutoimmune DiseasesAutoimmune ProcessBeta CellBiochemicalBiomedical EngineeringBiomimeticsCellsChildhoodChronicClinical TrialsCollectionCouplingCuesDevicesDiabetes MellitusDiagnosisDietDigestive System DisordersDiseaseDisease modelDockingEndocrineEngineeringEnvironmentEvaluationExtracellular MatrixFunctional disorderGasesGenerationsGoalsHealthHumanInstitutesInsulinInsulin-Dependent Diabetes MellitusInterventionIslets of LangerhansIslets of Langerhans TransplantationKidney DiseasesKnowledgeLeadLeftLiquid substanceMaintenanceMicrofluidic MicrochipsMicrofluidicsMissionModelingMonitorNational Institute of Diabetes and Digestive and Kidney DiseasesOxygenPancreasPathologyPharmacologic SubstancePhasePhysiologicalPlayPublic HealthRegulationReplacement TherapySamplingSourceStem cellsStructureStructure of beta Cell of isletSymptomsSystemTechnologyTestingTherapeuticTimeTissue EngineeringTransplantationbody systemcellular developmentcostculture platesdesigndiabetes managementdiabeticimprovedin vivoinnovationinsightinterestisletmicrosystemsmultidisciplinarynanofabricationnon-invasive monitorpreventprogenitorpublic health relevanceresearch studyresponsestem cell biology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: Engineering a Human Physiomimetic Islet Microsystem Type 1 diabetes mellitus, an autoimmune disease resulting in destruction of the insulin- producing pancreatic beta cells, is one of the most common and costly chronic pediatric diseases. A significant impediment to understanding disease pathology and the development of cellular replacement therapies for Type 1 diabetes is the inability to sustain mature human beta cells in culture. In this proposal, we seek to engineer physiomimetic 3D niches within microfluidics devices for maturation, maintenance, and monitoring of human beta cells via the convergence of technologies from stem cell biology, matrix engineering, micro/nano fabrication, and microsensors. The microfluidic devices will connect to universal docks and provide intimate control over the cellular microenvironment by independent and simultaneous modulation of liquid and gas phases, multiparameteric monitoring, and assessment of cellular readouts and samplers for off-line biochemical analyses. With this degree of control, the effect of various niche parameters on human islet maintenance and generation of mature islets from human pancreatic precursors can be clearly delineated. Of particular interest in this application are the
contributions of the physiological and extracellular matrix environment on islet health and maturation. Physiological oxygen, a critical parameter in steering pancreatic progenitor differentiation towards endocrine lineage, can be intimately modulated on the microscale via the control afforded by the microfabricated platform. Further, systematic evaluation of the contributions of matrix components on promoting islet health and directing islet differentiation within controlled 3D niches is feasible via tailored presentation of native extracellular matrix components. The ultimate goals of this proposal are twofold: 1) engineer a microfabricated "device and dock" system capable of providing microscale control of soluble and physiological conditions and agile assessment of multiple functional readouts in an enclosed, long-term culture system; and 2) utilize this innovative platform to systematically delineate critical factor capable of supporting both human islet maintenance and maturation of islet-like structures from human pancreatic progenitor cells. The project builds on recent breakthroughs by our team in creating microphysiological systems for other organ systems, engineering perifusion systems, matrix engineering, recreating oxygen controlled microenvironments, and progenitor differentiation. As such, the multidisciplinary consortium assembled herein is well poised to address these grand challenges.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/acs.jproteome.7b00160
发表时间:
2017-06-02
期刊:
Journal of proteome research
影响因子:
4.4
作者:
[Garcia-Contreras M, Tamayo-Garcia A, Pappan KL, Michelotti GA, Stabler CL, Ricordi C, Buchwald P]
通讯作者:
Buchwald P
Microelectrode Array based Functional Testing of Pancreatic Islet Cells.
基于微电极阵列的胰岛细胞功能测试。
DOI:
10.3390/mi11050507
发表时间:
2020
期刊:
Micromachines
影响因子:
3.4
作者:
[Alassaf,Ahmad, Ishahak,Matthew, Bowles,Annie, Agarwal,Ashutosh]
通讯作者:
Agarwal,Ashutosh
Engineering biomimetic materials for islet transplantation.
用于胰岛移植的工程仿生材料。
DOI:
10.2174/1573399811666150317130440
发表时间:
2015
期刊:
Current diabetes reviews
影响因子:
3.3
作者:
[Yang,EthanY, Kronenfeld,JoshuaP, Stabler,CherieL]
通讯作者:
Stabler,CherieL
Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions
-
批准号:10665727
-
项目类别:
-
资助金额:$99.45万
-
财政年份:2019
-
负责人:Ashutosh Agarwal
-
依托单位:
Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions
-
批准号:10453211
-
项目类别:
-
资助金额:$102.09万
-
财政年份:2019
-
负责人:Ashutosh Agarwal
-
依托单位:
Engineering a Human Microphysiological System for the Characterization of Islet-Immune Interactions
-
批准号:10467062
-
项目类别:
-
资助金额:$100.79万
-
财政年份:2019
-
负责人:Ashutosh Agarwal
-
依托单位:
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer
-
批准号:10458490
-
项目类别:
-
资助金额:$52.44万
-
财政年份:2018
-
负责人:Ashutosh Agarwal
-
依托单位:
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer
-
批准号:10001470
-
项目类别:
-
资助金额:$42.27万
-
财政年份:2018
-
负责人:Ashutosh Agarwal
-
依托单位:
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer
-
批准号:10216201
-
项目类别:
-
资助金额:$53.5万
-
财政年份:2018
-
负责人:Ashutosh Agarwal
-
依托单位:
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer
-
批准号:9631128
-
项目类别:
-
资助金额:$58.75万
-
财政年份:2018
-
负责人:Ashutosh Agarwal
-
依托单位:
海外基金